Inhibition of Histone Deacetylases: A Pharmacological Approach to the Treatment of Non-Cancer Disorders
The DOI matches its Crossref record.
Abstract
The dynamics of gene expression are regulated by histone acetylases (HATs) and histone deacetylases (HDACs) that control the acetylation state of lysine side chains of the histone proteins of chromatin. The catalytic activity of these two enzymes remodels chromatin to control gene expression without altering gene sequence. Treatment of cancer has been the primary target for the clinical development of HDAC inhibitors, culminating in approval for the first HDAC inhibitor for the treatment of cutaneous T cell lymphoma. Beyond cancer, HDAC inhibition has potential for the treatment of many other diseases. The HDAC inhibitors phenylbutyric acid, valproic acid, and suberoylanilide hydroxamic acid (SAHA) have been shown to correct errant gene expression, ameliorate the progression of disease, and restore absent synthetic or metabolic activities for a diverse group of non-cancer disorders. These benefits have been found in patients with sickle cell anemia, HIV, and cystic fibrosis. In vitro and in vivo models of spinal muscular atrophy, muscular dystrophy, and neurodegenerative, and inflammatory disorders also show response to HDAC inhibitors. This review examines the application of HDAC inhibition as a treatment for a wide-range of non-cancer disorders, many of which are rare diseases that urgently need therapy. Inhibition of the HDACs has general potential as a pharmacological epigenetic approach for gene therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They have also been demonstrated to possess greater isoform selectivity profiles, targeting specifically only the class I subgroup of HDACs (6-10, 26, 38, 39).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [10]
Citations
Cites
Still being checked.
Cited by
Delcuve, G. P., Khan, D. H., & Davie, J. R. (2012) · Clinical Epigenetics · doi:10.1186/1868-7083-4-5 · Cited by 505
Lauffer, B. E. L., Mintzer, R., Fong, R., Mukund, S., Tam, C., Zilberleyb, I., Flicke, B., Ritscher, A., Fedorowicz, G., Vallero, R., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.490706 · Cited by 429
Shukla, S., & Tekwani, B. L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00537 · Cited by 314
Engin, F., & Hotamisligil, G. S. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01282.x · Cited by 245
Histone deacetylases: structural determinants of inhibitor selectivity
Micelli, C., & Rastelli, G. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.01.007 · Cited by 192
Metadata
- Authors
- Wiech, N., Fisher, J., Helquist, P., & Wiest, O.
- Venue
- Current Topics in Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2009-02-01
- Volume
- 9
- Issue
- 3
- Pages
- 257-271
- ISSN
- 1568-0266 (ISSN-L)
- OpenAlex
- W2130332831
- Semantic Scholar
- 018b0a43682a3759cef7f8de29c9130eac7c7fd0
- Cited by
- 66
- References
- 0
- Citations by year
- 2024: 1 · 2023: 2 · 2021: 1 · 2020: 3 · 2018: 3 · 2017: 2 · 2016: 4 · 2015: 2 · 2014: 8 · 2013: 6 · 2012: 5
- FWCI
- 4.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Topics in Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase inhibitors, histone acetyltransferase, chromatin remodeling, gene expression regulation, epigenetic therapy, sickle cell disease, HIV, cystic fibrosis, spinal muscular atrophy, muscular dystrophy, neurodegenerative diseases, inflammatory diseases, rare diseases, valproic acid, vorinostat, 4-phenylbutyric acid, cutaneous T-cell lymphoma
- MeSH terms
- Drug Therapy, Enzyme Inhibitors, Humans, Epigenesis, Genetic, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of Histone Deacetylases: A Pharmacological Approach to the Treatment of Non-Cancer Disorders. https://app.cochat.ai/papers/10.2174/156802609788085241
- The paper
- Wiech, N., Fisher, J., Helquist, P., & Wiest, O. (2009). Inhibition of Histone Deacetylases: A Pharmacological Approach to the Treatment of Non-Cancer Disorders. Current Topics in Medicinal Chemistry. https://doi.org/10.2174/156802609788085241
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.